Skip to main content
SpringerLink
Log in

Alzheimer-Demenz: Praxis und neue Entwicklungen

Neurodegenerative Erkrankungen

  • zertifizierte fortbildung
  • Published:
InFo Neurologie & Psychiatrie Aims and scope

Zusammenfassung

Nicht nur unsere Gesellschaft, sondern auch Ärzte sind nur unzureichend auf den prognostizierten Anstieg der Patientenzahlen mit Alzheimer-Demenz (AD) vorbereitet. Diese und zukünftige Generationen von Neurologen und Psychiatern werden sich intensiv mit der Diagnose und Behandlung von AD-Patienten, aber auch mit Fragen zur Pathogenese und Prävention auseinandersetzen müssen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2
3
4
5

Literatur

  1. Hardy J. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J Neurochem. August 2009;110(4):1129–34.

    Article  CAS  PubMed  Google Scholar 

  2. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 28. Januar 2010;362(4):329–44.

    Article  CAS  PubMed  Google Scholar 

  3. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, u. a. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature. 2. August 2012;488(7409):96–9.

    Article  CAS  PubMed  Google Scholar 

  4. Bradshaw EM, Chibnik LB, Keenan BT, Ottoboni L, Raj T, Tang A, u. a. CD33 Alzheimer’s disease locus: altered monocyte function and amyloid biology. Nat Neurosci. Juli 2013;16(7):848–50.

    Article  CAS  PubMed  Google Scholar 

  5. Petersen RC, Negash S. Mild cognitive impairment: an overview. CNS Spectr. Januar 2008;13(1):45–53.

    PubMed  Google Scholar 

  6. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, u. a. Current concepts in mild cognitive impairment. Arch Neurol. Dezember 2001;58(12):1985–92.

    Article  CAS  PubMed  Google Scholar 

  7. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, u. a. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. Januar 2010;9(1):119–28.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, u. a. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. Februar 2013;12(2):207–16.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, u. a. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 30. August 2012;367(9):795–804.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Stewart R. Subjective cognitive impairment. Curr Opin Psychiatry. November 2012;25(6):445–50.

    Article  Google Scholar 

  11. Jessen F, Wiese B, Bachmann C, Eifflaender-Gorfer S, Haller F, Kölsch H, u. a. Prediction of dementia by subjective memory impairment: eff ects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry. April 2010;67(4):414–22.

    Article  PubMed  Google Scholar 

  12. Van Harten AC, Visser PJ, Pijnenburg YAL, Teunissen CE, Blankenstein MA, Scheltens P, u. a. Cerebrospinal fluid Aß42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement J Alzheimers Assoc. September 2013;9(5):481–7.

    Article  Google Scholar 

  13. Kalbe E, Calabrese P, Fengler S, Kessler J. DemTect, PANDA, EASY, and MUSIC: cognitive screening tools with age correction and weighting of subtests according to their sensitivity and specifi city. J Alzheimers Dis JAD. 1. Januar 2013;34(4):813–34.

    Google Scholar 

  14. Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol. September 2007;645(9):1323–9.

    Article  PubMed  Google Scholar 

  15. Wesnes KA. Assessing change in cognitive function in dementia: the relative utilities of the Alzheimer’s Disease Assessment Scale-Cognitive Subscale and the Cognitive Drug Research system. Neurodegener Dis. 2008;5(3-4):261–3.

    Article  PubMed  Google Scholar 

  16. Storey E, Slavin MJ, Kinsella GJ. Patterns of cognitive impairment in Alzheimer’s disease: assessment and differential diagnosis. Front Biosci J Virtual Libr. 1. Mai 2002;7:e155–184.

    Article  Google Scholar 

  17. Thal DR, Braak H. [Post-mortem diagnosis of Alzheimer’s disease]. Pathol. Mai 2005;26(3):201–13.

    Article  CAS  Google Scholar 

  18. Spies PE, Slats D, Sjögren JMC, Kremer BPH, Verhey FRJ, Rikkert MGMO, u. a. The cerebrospinal fl uid amyloid beta42/40 ratio in the diff erentiation of Alzheimer’s disease from non- Alzheimer’s dementia. Curr Alzheimer Res. August 2010;7(5):470–6.

    Article  CAS  PubMed  Google Scholar 

  19. ohnson KA, Fox NC, Sperling RA, Klunk WE. Brain Imaging in Alzheimer Disease. Cold Spring Harb Perspect Med [Internet]. April 2012 [zitiert 6. Dezember 2013];2(4). Verfügbar unter: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312396/

    Google Scholar 

  20. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K, u. a. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 8. September 2009;73(10):754–60.

    Article  CAS  PubMed  Google Scholar 

  21. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, u. a. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 18. September 2013;79(6):1094–108.

    Article  CAS  PubMed  Google Scholar 

  22. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, u. a. Revising the defi nition of Alzheimer’s disease: a new lexicon. Lancet Neurol. November 2010;9(11):1118–27.

    Article  PubMed  Google Scholar 

  23. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA. The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc. Dezember 2004;52(12):2082–7.

    Article  PubMed  Google Scholar 

  24. Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res. 10. August 2011;221(2):555–63.

    Article  CAS  PubMed  Google Scholar 

  25. Sadowsky CH, Farlow MR, Meng X, Olin JT. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials. Int J Clin Pract. Januar 2010;64(2):188–93.

    Article  CAS  PubMed  Google Scholar 

  26. Grossberg G, Cummings J, Frölich L, Bellelli G, Molinuevo JL, Krahnke T, u. a. Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer’s disease. Am J Alzheimers Dis Other Demen. September 2013;28(6):583–91.

    Article  PubMed  Google Scholar 

  27. Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, u. a. Randomized, double-blind, parallel-group, 48-week study for effi cacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm2) in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012;33(5):341–53.

    Article  CAS  PubMed  Google Scholar 

  28. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, u. a. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 18. Januar 2011;76(3):280–6.

    Article  CAS  PubMed  Google Scholar 

  29. Grossberg GT, Pejovic V, Miller ML, Graham SM. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer’s disease. Dement Geriatr Cogn Disord. 2009;27(2):164–72.

    Article  CAS  PubMed  Google Scholar 

  30. Schneider LS, Dagerman KS, Higgins JPT, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol. August 2011;68(8):991–8.

    Article  PubMed  Google Scholar 

  31. Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 21. Januar 2013;5(1):6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Scheltens P, Twisk JWR, Blesa R, Scarpini E, von Arnim CAF, Bongers A, u. a. Efficacy of Souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial. J Alzheimers Dis JAD. 2012;31(1):225–36.

    CAS  Google Scholar 

  33. Scheltens P, Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Wurtman RJ, Wilkinson D, u. a. Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial. Alzheimers Dement J Alzheimers Assoc. Januar 2010;6(1):1–10.e1.

    Article  CAS  Google Scholar 

  34. Birks J, Flicker L. Selegiline for Alzheimer’s disease. Cochrane Database Syst Rev. 2003;(1):CD000442.

    PubMed  Google Scholar 

  35. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, u. a. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 9. Juni 2005;352(23):2379–88.

    Article  CAS  PubMed  Google Scholar 

  36. Lloret A, Badía M-C, Mora NJ, Pallardó FV, Alonso M-D, Viña J. Vitamin E paradox in Alzheimer’s disease: it does not prevent loss of cognition and may even be detrimental. J Alzheimers Dis JAD. 2009;17(1):143–9.

    CAS  Google Scholar 

  37. Aisen PS, Cummings J, Schneider LS. Symptomatic and nonamyloid/ tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med. März 2012;2(3):a006395.

    Article  PubMed  Google Scholar 

  38. Vellas B, Coley N, Ousset P-J, Berrut G, Dartigues J-F, Dubois B, u. a. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. Oktober 2012;11(10):851–9.

    Article  CAS  PubMed  Google Scholar 

  39. Schneider LS. Ginkgo and AD: key negatives and lessons from GuidAge. Lancet Neurol. Oktober 2012;11(10):836–7.

    Article  PubMed  Google Scholar 

  40. Sink KM, Holden KF, Yaff e K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA J Am Med Assoc. 2. Februar 2005;293(5):596–608.

    Article  CAS  Google Scholar 

  41. Nepal B, Brown L, Ranmuthugala G. Modelling the impact of modifying lifestyle risk factors on dementia prevalence in Australian population aged 45 years and over, 2006-2051. Australas J Ageing. September 2010;29(3):111–6.

    Article  PubMed  Google Scholar 

  42. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kåreholt I, Winblad B, u. a. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol. Oktober 2005;62(10):1556–60.

    Article  PubMed  Google Scholar 

  43. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 23. August 2005;65(4):545–51.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology. 30. September 2008;71(14):1057–64.

    Article  CAS  PubMed  Google Scholar 

  45. Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev Off J Int Assoc Study Obes. Mai 2011;12(5):e426–437.

    Article  CAS  Google Scholar 

  46. Rozzini L, Vicini Chilovi B, Bellelli G, Bertoletti E, Trabucchi M, Padovani A. Effects of cholinesterase inhibitors appear greater in patients on established antihypertensive therapy. Int J Geriatr Psychiatry. Juni 2005;20(6):547–51.

    Article  PubMed  Google Scholar 

  47. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, u. a. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 8. September 2009;73(10):768–74.

    Article  CAS  PubMed  Google Scholar 

  48. Maier W., Jessen W, Schneider F, Deuschl G, Spottke A, Reichmann R. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, Deutsche Gesellschaft für Neurologie. Diagnose- und Behandlungsleitlinie Demenz, Interdisziplinäre S3 Praxisleitlinien Volume 2010, Springer Verlag ISBN: 978-3-642-13091-5 (Print) 978-3-642-13092-2 (Online)

    Chapter  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Neurologie, KBFZ, Universität Bonn, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Deutschland

    Michael T. Heneka

Authors
  1. Michael T. Heneka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael T. Heneka.

Additional information

Interessenkonflikt

Der Autor erklärt, dass er sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließ. Er erklärt Beratungs- und Vortragstätigkeit für die Firmen Pfizer, Novartis, Nutrica, Genfit S.A. und Dainippon Sumitomo Pharmaceuticals. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenaus-gabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen ent-halten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heneka, M.T. Alzheimer-Demenz: Praxis und neue Entwicklungen. InFo Neurologie 16, 40–51 (2014). https://doi.org/10.1007/s15005-014-0002-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-014-0002-8

Search

Navigation